Hemoperfusion in Extracorporeal Membrane Oxygenation (ECMO) Patients

Status Recruiting

Clinical Trial Summary

Extracorporeal membrane oxygenation (ECMO) is a temporary mechanical circulatory support device for cardiogenic shock (CS) patients. During extracorporeal membrane oxygenation (ECMO) support, the inflammatory response is intense and complex. It may cause infection, cell damage, organ dysfunction and even death. Hemoperfusion can adsorb inflammatory factors and reduce the inflammatory reaction. CS patients who are likely to receive veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support will be enrolled and randomized with a 1:1 allocation to a simultaneous hemoperfusion arm vs. standard care arm. 1. The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. 2. The patients in the standard care arm will not receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. The primary outcome is the change of plasma interleukin (IL)-6 level after hemoperfusion is commenced.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03729765
Study type	Interventional
Source	Beijing Anzhen Hospital
Contact	Xiaotong Hou, PhD., Md.
Phone	86 18911662932
Email	xt.hou@ccmu.edu.cn
Status	Recruiting
Phase	N/A
Start date	October 19, 2018
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03283995` - Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
Active, not recruiting	`NCT04325035` - The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock	Phase 2
Active, not recruiting	`NCT05100836` - SURPASS Impella 5.5 Study
Not yet recruiting	`NCT05106491` - Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients	N/A
Completed	`NCT02301819` - ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock	N/A
Completed	`NCT01367743` - Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock	Phase 4
Recruiting	`NCT05728359` - Genomic Determinants of Outcome in Cardiogenic Shock
Recruiting	`NCT05699005` - Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO	Phase 1
Not yet recruiting	`NCT06338345` - Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients	N/A
Completed	`NCT03436641` - Microcirculation in Cardiogenic Shock
Recruiting	`NCT03313687` - SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
Recruiting	`NCT05506449` - The RECOVER IV Trial	N/A
Completed	`NCT04144660` - "Treatment Use of ECMO In Pregnancy or Peripartum Patient."
Completed	`NCT04548739` - Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
Recruiting	`NCT04141410` - Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
Not yet recruiting	`NCT05879276` - Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.	Phase 3
Enrolling by invitation	`NCT05570864` - Score TO Predict SHOCK - STOP SHOCK
Completed	`NCT02591771` - Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock	Phase 2
Terminated	`NCT02279979` - Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial	N/A
Completed	`NCT01374867` - CardShock Study and Registry	N/A